#China #Beijing #AI Solutions #Biomanufacturing #Tsingke Biotech

Tsingke Biotech Unveils AI-Driven Biomanufacturing Solutions at the 2025 Festival of Biologics

Beijing Tsingke Biotech Co., Ltd. has made waves at the 2025 Festival of Biologics in Basel, Switzerland, presenting its AI-supported biomanufacturing platforms that aim to transform how products in biotechnology are developed and produced. The festival served as a gathering point for over 2,000 biotech professionals from various corners of the globe to witness next-generation advancements in the sector. Tsingke’s display highlighted its capabilities in gene and RNA design, antibody discovery, and the production of GMP-grade biologics, effectively demonstrating the integration of cutting-edge technology into traditional biomanufacturing practices.

In recent years, the line between research and manufacturing has become increasingly indistinct. Experts like Nan Zhang, Marketing Manager at Tsingke Biotech, noted that scientists now regularly validate manufacturability during the research phase—allowing for faster adoption of innovative discoveries from lab to market. This shift signals a promising future for both academic and industrial sectors within biotechnology.

Key Features of Tsingke's Offerings

Tsingke stood out at the festival with its full-scope molecular manufacturing solutions, featuring processes that range from DNA/RNA synthesis to antibody expression. The company's integrated platform is designed to streamline the transition from pioneering research to large-scale production. Key capabilities presented included:

• - High-throughput gene synthesis: This process leverages modified primers, crucial for epitope mapping, and reflects cutting-edge gene development techniques.
• - Chemically modified oligonucleotides: These play a fundamental role in advanced research and development efforts for antibody-drug conjugates (ADCs), PROTACs, and AOCs.
• - Optimized nucleic acid purification: With techniques for LNP encapsulation, Tsingke enhances the efficiency and effectiveness of its production pipelines.

These advancements position Tsingke at the forefront of responding to emerging industry trends, illustrating a commitment to advancing biologics that are not only innovative but also practical for therapeutic uses.

Bridging Science and Industry

The overarching vision driving Tsingke Biotech, referred to as “The Great Tsingke Gene Factory”, emphasizes biomanufacturing automation and digital design synergy. By utilizing advanced digital design and precision synthesis methods, Tsingke manages to enhance its manufacturing capabilities significantly. Zhang reiterated the importance of the Festival of Biologics in demonstrating how scientific breakthroughs can be aligned with industrial applications, asserting that this collaboration will shape the future of biomanufacturing.

Travelling back to its core mission, Tsingke is dedicated to empowering researchers worldwide with leading-edge solutions in drug discovery and genetic engineering. Operating within ISO 13485-certified facilities and Class 100,000 cleanrooms, the company promises high-quality and reliable output, essential for its clients engaged in therapeutic development.

Future Prospects

The presentation at the Festival of Biologics symbolizes Tsingke's ongoing commitment to meet the needs of an evolving biotechnology landscape. With its advanced platforms and commitment to innovation, Tsingke Biotech is positioned to not just participate in but actively lead the transformation of biomanufacturing practices. Through ongoing research and integration of AI in biomanufacturing, Tsingke promises to pave the way for the next generation of biologics that promise efficient solutions for scientists and institutions worldwide.

For the latest updates and insights, Tsingke Biotech encourages the industry to follow their developments on LinkedIn, ensuring stakeholders remain engaged with advancements that shape the future of biotechnology.

Contact: [email protected]